Creasey W A, Platt T B, Frantz M, Sugerman A A
Br J Clin Pharmacol. 1985 Feb;19(2):233-7. doi: 10.1111/j.1365-2125.1985.tb02636.x.
The pharmacokinetics of aztreonam were studied in 12 healthy male volunteers aged 65 to 75 years who received 1 g of the antibiotic intravenously. Data were fitted to a two-compartment open model to yield the following parameters: t 1/2, lambda 1, 0.15 h; t 1/2,z, 2.06 h; area under the 24-h serum concentration-time curve, 231.8 micrograms ml-1 h; Cmax, 120.1 micrograms/ml; V1 area, 0.16 l/kg; and serum clearance, 0.94 ml min-1 kg. Twenty-four hour urinary elimination reached 63.1% of dose as aztreonam and 3.1% as the open ring metabolite SQ 26,992. These data were similar to those obtained for healthy males aged 18 to 35 years. Thus, age per se is not a major therapeutic consideration in treating elderly patients, and other factors, primarily the parameters of renal function, should serve as the basis for any dose reduction.
对12名年龄在65至75岁的健康男性志愿者进行了氨曲南的药代动力学研究,这些志愿者静脉注射了1克该抗生素。数据拟合到二室开放模型以得出以下参数:t 1/2,λ1,0.15小时;t 1/2,z,2.06小时;24小时血清浓度-时间曲线下面积,231.8微克·毫升⁻¹·小时;Cmax,120.1微克/毫升;V1面积,0.16升/千克;以及血清清除率,0.94毫升·分钟⁻¹·千克。24小时尿液排泄量达到剂量的63.1%(以氨曲南形式)和3.1%(以开环代谢物SQ 26,992形式)。这些数据与18至35岁健康男性获得的数据相似。因此,年龄本身并非治疗老年患者的主要治疗考虑因素,其他因素,主要是肾功能参数,应作为任何剂量降低的依据。